Connect with us

Economy

European Commission will buy up to 300 million doses of the Pfizer and BioNTech vaccine

SHARE:

Published

6 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

Following today’s (10 November) announcement by Pfizer and BioNTech that their mRNA-based vaccine against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, the EU announced that it was already in talks with the companies and it would procure 300 millions doses of the vaccine.

Dr. Albert Bourla, Pfizer Chairman and CEO, said: “With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

Prof. Ugur Sahin, BioNTech co-founder and CEO, said: “The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort.” 

In a statement, European Commission President Ursula von der Leyen said:  “A safe and effective vaccine is our best chance to beat coronavirus and return to our normal lives. In the past months, the European Commission has been working tirelessly to secure doses of potential vaccines.

“Tomorrow (11 November) we authorize a contract for up to 300 million doses of the vaccine developed by German company BioNTech and Pfizer. This is the most promising vaccine so far.

“Once this vaccine becomes available, our plan is to deploy it quickly, everywhere in Europe. This will be the fourth contract with a pharmaceutical company to buy vaccines. And more will come. Because we need to have a broad portfolio of vaccines based on different technologies.

Advertisement

“We have already started working with Member States to prepare national vaccination campaigns.

“We are almost there. In the meantime, let us be prudent, and stay safe.”

Based on current projections, Pfizer expect to produce up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending